Close menu




March 17th, 2021 | 07:25 CET

Fresenius SE, Q+M Dental Group, Siemens Healthineers: Where growth meets dividends

  • Healthcare
Photo credits: pixabay.com

The back-and-forth surrounding AstraZeneca's vaccine has unsettled many people. But the discussion about extremely rare side effects also shows: Vaccines and drugs are subject to strict regulations and the healthcare system is strictly regulated. While pharmaceutical companies must always expect setbacks, especially in accelerated approval procedures, the situation is different for suppliers of medical technology or consumables. We present three stocks that are benefiting from rising healthcare spending.

time to read: 3 minutes | Author: Nico Popp
ISIN: DE0005785604 , SG2E73981531 , DE000SHL1006

Table of contents:


    Fresenius: Solid but no more

    Fresenius is a Company based in Bad Homburg, Germany, that has dedicated itself entirely to dialysis. When patients suffer kidney failure, this form of blood washing using technical equipment is often the only way to bridge the time until a transplant. The dialysis business accounts for about 50% of sales, artificial nutrition for another 20% and the hospital Company Helios for more than 25%. The hospital services business accounts for about 5%. Fresenius' figures have recently been mediocre: although sales have increased, profits have been lackluster.

    Moreover, the share price has been flat for 3 months: the bottom line is a loss of 5.6%. Although Fresenius, focusing on dialysis and its other pillars, is a potential beneficiary of rising healthcare system expenditures, the word is not yet out in the market. Investors who invest for the long term and can tolerate a fair amount of boredom in their portfolio see Fresenius as a dividend stock: around 2.3% yield beckons in this way.

    Q&M Dental: The Asian dividend stock with growth fantasy

    Q&M Dental is also a dividend stock. The penny stock from Singapore is only a small company at first glance. The operator of 5 dental clinics and 114 practices took an early stake in a manufacturer of corona tests last year and is working with official agencies in Singapore, among others, on the application of these tests, and has put out feelers in other countries. The combination of dental treatments and corona tests seems to be a profitable business for Q&M. In addition to the strong financials, the Company announced a special dividend in early March, in addition to its regular dividend. Overall, the stock brings a dividend yield of around 5% to all investors who have been shareholders in recent weeks.

    In addition to its bread-and-butter business of dental treatments, Q&M Dental also sees itself as an innovative company and aims to score points with artificial intelligence in everyday dental practice. The franchise system for dental practices is to be further expanded. Given the success of recent years, it is evident that this will succeed: many dentists seem to feel extremely comfortable under the Q&M umbrella. Since the Company is not only active in Singapore, the share offers investors a comprehensive Asian fantasy and adds to that the test kit business, which Q&M is expected to do for some time to come. The stock has been kissed awake in recent weeks but is still trading under the radar of many investors.

    Siemens Healthineers: Surprises loom here

    By contrast, the Siemens Healthineers share is much better known. The Company offers equipment related to imaging and diagnostics. Last year, many examinations were postponed or canceled altogether due to the pandemic. As a result, Siemens Healthineers' figures at the end of last year were not so rosy either. But the Company took countermeasures and launched a share buyback last fall. Most recently, Siemens Healthineers announced a stable dividend and thus convinced the market of its merits. Many investors believe that the preventive medical checkup business will return to robust growth in the future. The stock has climbed 14% in the past 3 months and looks promising from a chart perspective. It should only be a matter of time before the share rises above EUR 50.

    After that, it will be necessary for Siemens Healthineers to be able to surprise the market. Given the sluggish vaccination business in Germany, it cannot be ruled out that business in the first two quarters of 2021 will again be somewhat less good. The share price could then also run out of steam. Investors who want to sit out this phase can still buy the stock. Those who like it more dynamic should take a closer look at Q&M. Here, Covid-19 fantasy meets a proven business with dental treatments, which is also to be further expanded. Q&M Dental Group's recent dividend could set the tone for the future.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Juliane Zielonka on February 22nd, 2024 | 07:00 CET

    Royal Helium, Fresenius, BASF: Chemical and Healthcare industry - Where is the next investment opportunity?

    • Helium
    • Healthcare
    • chemicals

    Europe is in the midst of an industrial upheaval due to the Green Deal, which presents both challenges and opportunities for investors. While companies like BASF are arguing for deregulation and increased subsidies to support the green transition, healthcare company Fresenius is undergoing a period of radical change and realignment. The medical technology market is booming. The global MedTech market size amounted to USD 574,002.45 million in 2022 and is expected to increase to USD 814,159.2 million by 2028, with an annual growth rate of 6.0%. Critical raw materials such as helium are in particularly high demand. Royal Helium is one of the producers of this valuable gas and impresses with a well thought-out and sustainable business model. Where does the next investment opportunity lie?

    Read

    Commented by Juliane Zielonka on December 7th, 2023 | 07:00 CET

    New developments in the healthcare market: Cardiol Therapeutics, Amazon and Bayer shares in focus

    • Biotechnology
    • Pharma
    • Healthcare

    Cardiol Therapeutics, a clinical-stage life sciences company focusing on therapies for heart inflammation, has secured a renowned clinic to advance its Phase II MAvERIC-Pilot study. This study, focused on combating recurrent pericarditis, promises to provide sound approaches to improve the quality of life of affected patients. Amazon has been dabbling in the healthcare sector since 2015 and is gradually conquering the telemedicine market. The path to telemedicine for Prime members, through the acquisition of companies such as "One Medical" and "PillPack", poses challenges. In contrast, Bayer is once again caught in the crossfire of legal disputes. The recent glyphosate trial loss before a jury in Philadelphia calls for a strategic realignment. At the same time, Bayer is attempting to provide new impetus in the area of women's health through a partnership in the field of hormonal contraception. Find out which development holds promise here.

    Read

    Commented by Juliane Zielonka on November 23rd, 2023 | 07:20 CET

    Saturn Oil + Gas, Rheinmetall, Bayer - Energy, Defense, Healthcare: Where short-term returns await

    • Mining
    • Oil
    • defense
    • Healthcare

    In Germany, the federal government put its spending on hold, a day after the Federal Constitutional Court ruled that the reallocation of EUR 60 billion of unused debt from the pandemic era to the Energy and Climate Fund was unlawful. Europe's largest economy is shrinking due to rising energy prices and trade tensions. At the same time, North America, with stable oil companies such as Saturn Oil & Gas, presents an attractive investment opportunity for investors. Rheinmetall is experiencing a target price high of EUR 370 and flirting with long-term prospects in the US. At the same time, Bayer grapples with legal challenges and the failure of the blood thinner 'asundexian'. We look at where an investment may be worthwhile now.

    Read